Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Am J Cardiol. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2691892

Clinical and Research Applications of Carotid Intima-Media Thickness


Cardiovascular imaging modalities such as coronary computed tomography, carotid ultrasonography, and cardiovascular magnetic resonance imaging are increasingly being utilized to measure cardiovascular disease progression. Imaging measures, most notably carotid intima-media thickness (CIMT), are being applied as surrogate markers for clinical endpoints such as myocardial infarction and death in clinical trials. Clinicians and their patients are faced with the challenge of evaluating these imaging measures for their efficacy and practicality in clinical practice, as well as in clinical trials. We conclude from a review of clinical trials and guidelines that CIMT measurement may be useful in evaluating cardiovascular disease risk in select patient populations but may not always be an appropriate surrogate for clinical endpoints. While CIMT has clear advantages over alternative cardiovascular imaging modalities, ultimately prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.

Keywords: Carotid intima-media thickness, Atherosclerosis, Carotid arteries


Advances in cardiovascular imaging have the potential to improve early detection of atherosclerotic vascular disease and quantify its progression. Clinicians and their patients are challenged with how best to integrate these emerging modalities into clinical practice and understand their implications as surrogate markers for clinical endpoints in trials. The use of carotid intima-media thickness (CIMT) as a surrogate marker of clinical events such as myocardial infarction exemplifies this challenge. The recent publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has provoked debate over the use of CIMT as a surrogate endpoint in clinical trials and has called into question the use of a drug currently taken by millions of patients worldwide.1 This article examines the utility of CIMT as a proxy for cardiovascular disease events and provides a framework for interpreting the results of the ENHANCE trial and other studies using CIMT as the primary endpoint.

CIMT Measurement

The American Society of Echocardiography (ASE) 2008 Consensus Statement on Carotid Intima-Media Thickness defines CIMT as the combined thickness of the intimal and medial layers of the far arterial wall of the carotid artery.2 Carotid plaque is defined as focal arterial wall thickening that is at least 50% greater than the surrounding wall or a focal region of CIMT > 1.5 mm.2 While standard carotid duplex ultrasonography is primarily used to identify occlusive carotid plaque (advanced atherosclerosis), CIMT assessment measures arterial wall thickening (pre-atherosclerosis) and non-occlusive plaque formation (subclinical atherosclerosis).

The ASE 2008 Consensus Statement has set forth guidelines for the measurement of CIMT (see Table 1 for full guidelines).2 Carotid ultrasound imaging should follow a scanning and reporting protocol similar to those used in large research studies such as the Atherosclerosis Risk in Communities (ARIC) study,3 using: a state-of-the-art ultrasound system; a standardized definition for carotid plaque; CIMT measurements taken exclusively from the far wall of the common carotid artery, with scanning of other portions of the carotid arteries only to search for carotid plaque; B-mode imaging in preference to M-mode imaging; 3-to-5 beat cine-loop and electrocardiographic R-wave gated still frames to optimize accuracy of CIMT measurements.

Table 1
American Society of Echocardiography 2008 Consensus Statement guidelines for carotid intima-media thickness (CIMT) measurement.2

Normal CIMT values have been defined based on age and gender distribution curves within a general healthy population, as reported in the ARIC study (Table 2).4 The ASE consensus statement concludes that CIMT values that are ≥ 75th percentile suggest risk higher than that predicted by the Framingham Risk Estimate (FRE), and should be regarded as “high” values.2 Values that fall within the 25th to 75th percentile ranges are considered “average” and should not affect traditional risk estimates. Values that are ≤ 25th percentile are “low” and suggest risk lower than that predicted by the FRE.

Table 2
Carotid intima-media thickness values, adjusted for age, field center, race, and sex, adapted from the Atherosclerosis Risk in Communities Study.4

CIMT and Cardiovascular Disease Risk

CIMT is associated with risk of stroke, myocardial infarction, and death from coronary causes in several large observational studies.5 In the ARIC study, investigators examined the association between CIMT and coronary heart disease over 4 to 7 years in 12,841 individuals (57% women), aged 45–64, who were clinically free of disease at baseline.4 Hazard ratios for coronary heart disease comparing individuals with mean CIMT ≥ 1 mm to individuals with mean CIMT < 1 mm, after adjustment for age, race, and study center, were 5.07 for women (95% CI, 3.08 – 8.36) and 1.85 for men (95% CI, 1.28 – 2.69). A systematic review and meta-analysis of eight large population-based observational studies (including over 37,000 patients) of CIMT and cardiovascular disease risk concluded that for an absolute CIMT difference of 0.1 mm, the future risk of myocardial infarction increased by 10%–15%, and the stroke risk increased by 13%–18%.5

While the data supporting CIMT association with coronary artery disease is strongest for individuals between the ages of 42 and 74, a few studies have demonstrated a strong relationship between risk factor burden and CIMT in younger individuals (18 to 42 years old).6, 7 The Bogalusa Heart Study, a community-based epidemiological study of the early natural history of cardiovascular disease in children and young adults from the semirural, biracial community of Bogalusa, Louisiana, demonstrated an association of CIMT with an increased number of cardiovascular risk factors (smoking, high total cholesterol to HDL cholesterol ratio, high systolic blood pressure, large waist circumference, and high insulin level).8, 9 Further, increased CIMT is seen in individuals with familial hypercholesterolemia and the metabolic syndrome.911

Given the relationship between CIMT and traditional cardiovascular risk factors, it is important to consider whether CIMT offers incremental information beyond the risk factors. After adjustment for many possible confounders—age, race, study center, LDL cholesterol, HDL cholesterol, body mass index, sports activity, cigarette-years, hypertension, diabetes mellitus, ethanol use, and fibrinogen—the ARIC study showed hazard ratios for coronary heart disease comparing mean CIMT more vs. less than 1 mm to be 2.62 for women (95% CI, 1.55 – 4.46) and 1.20 for (95% CI, 0.81 – 1.77) (compare to numbers above, adjusted only for age, race, and study center), suggesting that CIMT may add prognostic information to risk prediction based on traditional risk factors, particularly in women.4

Even though CIMT is predictive of coronary heart disease, it is not clear how much the pathobiological processes underlying the 2 phenomena overlap. A novel locus on chromosome 9p has been identified as the strongest common genetic risk factor for myocardial infarction and coronary artery disease, and the same locus is associated with coronary artery calcification.12, 13 However, this locus does not appear to be associated with CIMT,14, 15 underscoring that CIMT is at least partly distinct from coronary atherosclerosis and thus will not fully mirror cardiovascular disease events, either in the context of a predictor of risk or that of a surrogate endpoint.

CIMT Versus Other Imaging Measures

Coronary artery calcification (CAC) measurement and cardiovascular magnetic resonance imaging (CMR) are 2 additional non-invasive imaging modalities used to assess atherosclerotic disease progression. A recent study from the Multi-Ethnic Study of Atherosclerosis (MESA) compared CAC to CIMT in predicting cardiovascular disease incidence in 6,698 individuals, aged 45 to 84, who were asymptomatic and free of cardiovascular disease at baseline.16 The study found that compared to CIMT, CAC was more strongly associated with incident cardiovascular disease in the overall population. In the subgroup analysis of individuals with intermediate FRE scores, CAC was also more predictive than CIMT, with multivariable-adjusted hazard ratios of 1.8 (95% CI, 1.4 – 2.2) for the former and 1.4 (95% CI, 1.1 – 1.6) for the latter. In contrast, CIMT was found to be a modestly better predictor of stroke, perhaps the result of the difference between vascular territories targeted by the 2 measures. The major disadvantage of measurement of CAC compared to CIMT is exposure to ionizing radiation.

CMR provides high-resolution, 3-dimensional capabilities to measure atherosclerotic plaque burden in arterial walls. CMR has been used to assess atherosclerotic disease progression in the carotid arteries, aorta, and coronary arteries.17 The technique also provides detailed information about plaque composition, which may eventually play a role in predicting plaque vulnerability to rupture.18 Multiple studies of statin therapies have demonstrated both regression and decreased progression of atherosclerotic plaque as measured by CMR.1921 Compared to CIMT measurement, the major advantage of CMR is the ability to directly image the coronary arteries and perhaps characterize unstable plaques; the major disadvantage is the high cost of the study compared to ultrasonography.22

CIMT as an Endpoint in Trials

Observational studies and interventional trials using adverse cardiovascular events such as myocardial infarction and death from cardiovascular causes as endpoints often require large populations, years of follow-up, and considerable financial resources. With the establishment of an association between CIMT and cardiovascular disease risk, an increasing number of trials are utilizing CIMT as a surrogate endpoint for clinical events. The clear advantage is that CIMT allows investigators to monitor for changes in a study’s endpoint with a therapy—progression or regression of CIMT—significantly earlier and with fewer participants than would be required with clinical endpoints such as myocardial infarction, reducing the time and expenses spent on the study. Compared to other imaging modalities, such as CAC, CMR, quantitative coronary angiography (QCA), and intravascular ultrasonography (IVUS) of the coronary arteries, CIMT measurement has the advantages of being non-invasive, radiation-free, relatively easy to acquire regardless of patient anatomy, relatively inexpensive, and reliant on widely available equipment.

Is CIMT a legitimate proxy endpoint for cardiovascular events? Espeland et al. examined whether CIMT fulfills established clinical and statistical criteria for surrogate endpoints.23 The analysis was based on 7 placebo-controlled trials of statins, published between 1994 and 2002, that reported both CIMT and cardiovascular outcomes.23 Two sets of criteria were used to evaluate surrogacy: Boissel et al. defined surrogacy with the 3 parameters of efficiency, linkage, and congruency;24 Prentice’s 4 criteria comprised the impact of the intervention on the endpoint, the impact on CIMT, the link between CIMT and cardiovascular events, and conditional independence between statin therapy and cardiovascular events given CIMT.25 CIMT was judged to meet all 3 of the Boissel criteria but only the first 3 of the 4 Prentice criteria, with the exception of one meta-analysis study that was felt to support the fourth criterion.26 Based on these analyses, the authors concluded that CIMT progression met accepted definitions of a surrogate marker for cardiovascular endpoints in statin trials.23 The possibility remains that while statins reduce CIMT progression and cardiovascular events in tandem fashion, making the former a good surrogate for the latter, other lipid-modifying medications may not.

Two significant trials involving lipid-lowering therapy and CIMT that have since been published include The Measuring Effect on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) trial27 and, more recently, the ENHANCE trial.1 METEOR evaluated the effect of rosuvastatin on CIMT over 2 years in 984 asymptomatic low-risk individuals (middle-aged individuals with FRE ≤ 10%) with evidence of subclinical atherosclerosis. Rosuvastatin resulted in a nonsignificant regression of CIMT (−0.0014 mm/yr), in contrast to the progression of CIMT seen in the placebo arm (+0.0131 mm/yr; P < 0.001 for rosuvastatin vs. placebo).27 The rosuvastatin group also experienced a 49% reduction in LDL cholesterol. While METEOR was not a clinical outcomes-based trial, the effect on CIMT was consistent with an expectation for improvement in clinical outcomes based on other statin-based trials. This expectation was borne out with the early termination of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, in which an overwhelming clinical benefit was seen with rosuvastatin in primary prevention patients.28

The ENHANCE trial was published shortly after the release of the ASE Consensus Statement and has become one of the most provocative trials in cardiology.1 The investigators conducted a double-blind, randomized trial over 2 years comparing the effects of simvastatin paired with a placebo vs. the combination of simvastatin and ezetimibe in patients with familial hypercholesterolemia. The primary endpoint was the change in the mean CIMT thickness (average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries). The mean CIMT thickness was 0.0058 mm in the simvastatin-only group and 0.0111 mm in the simvastatin plus ezetimibe group, with a difference in means of 0.0053 mm (P = 0.29). The apparent 47% increase in CIMT in the combination group compared to the simvastatin-only group—which was not statistically significant—led to public statements by thought leaders in cardiology and by the mass media denouncing the use of ezetimibe as potentially increasing risk of cardiovascular disease.

ENHANCE undoubtedly drew much attention because it was one of the first trials to demonstrate an apparently negative—albeit not statistically significant—effect of a lipid-lowering agent on a surrogate for cardiovascular disease events. What has not received as much attention as the negative CIMT findings of ENHANCE is the unambiguous improved reduction in LDL cholesterol in the combination group compared to the simvastatin-only group (16% increased reduction in LDL cholesterol).1 Reduction of these markers in statin trials have been consistently associated with reduction of rates of cardiovascular events.29 Thus, ENHANCE showed a discordance between 2 widely used surrogates for cardiovascular events—LDL cholesterol and CIMT—and it remains unclear which is the “correct” surrogate in this trial.

ENHANCE demonstrated both the need for standardization of CIMT protocols and the potentially serious consequences for clinical practice if surrogate markers are inappropriately utilized. To exclude ezetimibe based on nonsignificant changes in CIMT alone in a study where about 80% of subjects were on prior lipid-lowering therapy—particularly when significant LDL cholesterol reductions were seen with the drug—seems premature. Ultimately, the ongoing clinical outcomes-based trial evaluating the combination therapy versus simvastatin alone in reducing post-acute-coronary-syndrome cardiovascular events [Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)] will more definitively establish whether ezetimibe has meaningful clinical efficacy,30 as well as whether CIMT or LDL cholesterol was the “correct” surrogate in ENHANCE.

CIMT in Clinical Practice

While one big challenge faced by preventive cardiologists and their patients is how best to interpret the results of trials using CIMT as the primary endpoint, another challenge is how to integrate new imaging measures such as CIMT into clinical practice. The ASE concluded that measuring CIMT and identifying carotid plaque may be useful in evaluating cardiovascular disease risk in the following patient populations:2

  • Individuals with intermediate cardiovascular disease risk (6%–20% 10-year risk of myocardial infarction by the FRE), to further define their cardiovascular disease risk and to guide therapy
  • Patients with family history of premature cardiovascular disease in a first-degree relative
  • Individuals younger than 60 years of age with severe single risk factor abnormalities (i.e., genetic dyslipidemias), who would otherwise not be candidates for pharmacotherapy
  • Women younger than 60 years of age with ≥ 2 cardiovascular disease risk factors

The consensus statement also suggests that CIMT can be used if the “burden of subclinical vascular disease” is unclear or if evaluation for the degree of aggressiveness of therapy is needed.2 CIMT measurement has not been recommended for patients in whom the results would not change treatment, such as in patients with established coronary atherosclerotic disease.

It is important to recognize that current recommendations for the clinical use of CIMT are based on observational studies. Further, the role of CIMT in an environment where a number of other novel markers, such as coronary artery calcium, hsCRP, and genetic polymorphisms, are being similarly advocated for clinical use remains unclear. Ultimately prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, Visseren FLJ, Sijbrands EJG, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia (ENHANCE) N Eng J Med. 2008;358:1431–1443. [PubMed]
2. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiography. 2008;21:93–111. [PubMed]
3. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151:478–487. [PubMed]
4. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 1997;146:483–494. [PubMed]
5. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–467. [PubMed]
6. Davis PH, Dawson JD, Mahoney LT, Lauer RM. Increased carotid intimal-media thickness and coronary calcification are related in young and middle-aged adults: the Muscatine study. Circulation. 1999;100:838–842. [PubMed]
7. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intima-media thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation. 2001;104:2815–2819. [PubMed]
8. Urbina EM, Srinivasan SR, Tang R, Bond MG, Kieltyka L, Berenson GS. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (the Bogulasa heart study) Am J Cardiol. 2002;90:953–958. [PubMed]
9. Tzou WS, Douglas PS, Srinivasan SR, Bond MG, Tang R, Chen W, Berenson GS, Stein JH. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogulasa Heart Study. J Am Coll Cardiol. 2005;46:457–463. [PubMed]
10. Chen W, Srinivasan SR, Xu J, Berenson GS. Effect of parental coronary artery disease on adverse effects of the metabolic syndrome and aging on carotid artery intima-media thickness (from the Bogulasa Heart Study) Am J Cardiol. 2008;102:180–183. [PubMed]
11. Ye Z, Cheng H, Chiou K, Charng M. Relation of C-reactive protein and carotid intima-media thickness in Taiwanese with familial hypercholesterolemia. Am J Cardiol. 2008;102:184–187. [PubMed]
12. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491. [PMC free article] [PubMed]
13. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE Study. Hum Mol Genet. 2008;7:2320–2328. [PMC free article] [PubMed]
14. Samani NJ, Raitakari OT, Sipilä K, Tobin MD, Schunkert H, Juonala M, Braund PS, Erdmann J, Viikari J, Moilanen L, Taittonen L, Jula A, Jokinen E, Laitinen T, Hutri-Kähönen N, Nieminen MS, Kesäniemi YA, Hall AS, Hulkkonen J, Kähönen M, Lehtimäki T. Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1679–1683. [PubMed]
15. Cunnington MS, Mayosi BM, Hall DH, Avery PJ, Farrall M, Vickers MA, Watkins H, Keavney B. Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis. 2008 doi: 10.1016/j.atherosclerosis.2008.06.025. [PMC free article] [PubMed] [Cross Ref]
16. Folsom AR, Kronmal RA, Detrano RC, O’Leary DH, Bild DE, Bluemke DA, Budoff MJ, Liu K, Shea S, Szklo M, Tracy RP, Watson KE, Burke GL. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA) Arch Intern Med. 2008;168:1333–1339. [PMC free article] [PubMed]
17. Desai MY, Bluemke DA. Atherosclerosis imaging using MR imaging: current and emerging applications. Magn Reson Imaging Clin N Am. 2005;13:171–180. [PubMed]
18. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation. 2002;106:2026–2034. [PubMed]
19. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G, Badimon JJ. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106–112. [PubMed]
20. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation. 2004;110:2336–2341. [PubMed]
21. Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, Kihara T, Sawada S, Iwamoto N, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol. 2005;45:733–742. [PubMed]
22. Thompson JB, Blaha M, Resar JR, Blumenthal RS, Desai MY. Strategies to reverse atherosclerosis: an imaging perspective. Curr Treat Options Cardiovasc Med. 2008;10:283–293. [PubMed]
23. Espeland MA, O’Leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intima-media thickness as a surrogate marker for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005;6:3. [PMC free article] [PubMed]
24. Boissel J-P, Collet J-P, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharm. 1992;43:235–244. [PubMed]
25. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statist Med. 1989;8:431–440. [PubMed]
26. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262–269. [PubMed]
27. Crouse JR, III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis (METEOR trial) JAMA. 2007;297:1344–1353. [PubMed]
28. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207. [PubMed]
29. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–345. [PMC free article] [PubMed]
30. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826–832. [PubMed]